Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03759717 · ClinicalTrials.gov registry record
Molecular and Cellular Characterization of Skull Base Tumors
A clinical trial of Skull Base Neoplasm and Cellular Pathology, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- 4,000
- Enrollment target
- 1
- Study location
NCT03759717: Recruiting study of Skull Base Neoplasm and Cellular Pathology, sponsored by University of Pittsburgh.
NCT03759717 is a study of Skull Base Neoplasm and Cellular Pathology that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 4,000 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03759717, a study of Skull Base Neoplasm and Cellular Pathology, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- 4,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to analyze biological samples and genetic material for basic science research investigating the molecular and cellular characterization of skull base tumors.
Primary Outcome
There will be one outcome measure: overall survival.
Conditions Studied
Interventions
- OTHER Observation
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2018-10-03 |
| Est. Completion | 2028-10-03 |
What NCT03759717 shows while recruiting
NCT03759717 is an observational study that tracks outcomes without assigning an intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 2 conditions, with Skull Base Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.
NCT03759717 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03759717 about?
NCT03759717 is a clinical study titled "Molecular and Cellular Characterization of Skull Base Tumors". The purpose of the study is to analyze biological samples and genetic material for basic science research investigating the molecular and cellular characterization of skull base tumors.
What is the current status of trial NCT03759717?
This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2018-10-03. Estimated completion is 2028-10-03.
What conditions does trial NCT03759717 study?
This clinical trial studies the following conditions: Skull Base Neoplasm, Cellular Pathology.
What interventions are being tested in trial NCT03759717?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT03759717?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03759717 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI